

E AND R AMENDMENTS TO LB 157

Introduced by Ballard, 21, Chairman Enrollment and Review

1           1. Strike the original sections and insert the following new  
2 sections:

3           Section 1. Section 25-21,273, Reissue Revised Statutes of Nebraska,  
4 is amended to read:

5           25-21,273 (1) Unless the petitioner is allowed to proceed in forma  
6 pauperis in accordance with sections 25-2301 to 25-2310, all All  
7 proceedings under sections 25-21,270 to 25-21,272 shall be at the cost of  
8 the petitioner ~~or petitioners~~, for which fee-bill or execution may issue  
9 as in civil cases.

10          (2) Any change of names under such the provisions of said sections,  
11 shall not in any manner affect or alter any right of action, legal  
12 process, or property.

13          Sec. 2. (1) A health care provider, an emergency medical services  
14 provider, a laboratory, or a pharmacy providing medical services,  
15 transportation, medications, or other services related to the examination  
16 or treatment of injuries arising out of sexual assault as defined in  
17 section 29-4309, domestic assault under section 28-323, or child abuse  
18 under section 28-707 shall not:

19          (a) Refer a bill for such services to a collection agency or an  
20 attorney for collection against the victim or the victim's guardian or  
21 family;

22          (b) Distribute information regarding such services and status of  
23 payment in any way that would affect the credit rating of the victim or  
24 the victim's guardian or family; or

25          (c) Take any other action adverse to the victim or the victim's  
26 guardian or family on account of providing such services.

27          (2) This section shall not be construed to prevent an entity

1 described in subsection (1) of this section from otherwise seeking  
2 payment for such services from the victim or any other source.

3 (3) If a collection agency or an attorney is referred a debt for a  
4 bill described in subsection (1) of this section, then upon notice of the  
5 applicability of this section, the collection agency or attorney shall  
6 return the debt to the referring health care provider, emergency medical  
7 services provider, laboratory, or pharmacy.

8 (4) No private cause of action shall exist under this section  
9 against a debt collector.

10 Sec. 3. Section 28-405, Revised Statutes Cumulative Supplement,  
11 2022, is amended to read:

12 28-405 The following are the schedules of controlled substances  
13 referred to in the Uniform Controlled Substances Act, unless specifically  
14 contained on the list of exempted products of the Drug Enforcement  
15 Administration of the United States Department of Justice as the list  
16 existed on January 31, 2022 ~~2021~~:

17 Schedule I

18 (a) Any of the following opiates, including their isomers, esters,  
19 ethers, salts, and salts of isomers, esters, and ethers, unless  
20 specifically excepted, whenever the existence of such isomers, esters,  
21 ethers, and salts is possible within the specific chemical designation:

22 (1) Acetylmethadol;

23 (2) Allylprodine;

24 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also  
25 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

26 (4) Alphameprodine;

27 (5) Alphamethadol;

28 (6) Benzethidine;

29 (7) Betacetylmethadol;

30 (8) Betameprodine;

31 (9) Betamethadol;

- 1 (10) Betaprodine;
- 2 (11) Clonitazene;
- 3 (12) Dextromoramide;
- 4 (13) Difenoquin;
- 5 (14) Diampromide;
- 6 (15) Diethylthiambutene;
- 7 (16) Dimenoxadol;
- 8 (17) Dimepseptanol;
- 9 (18) Dimethylthiambutene;
- 10 (19) Dioxaphetyl butyrate;
- 11 (20) Dipipanone;
- 12 (21) Ethylmethylthiambutene;
- 13 (22) Etonitazene;
- 14 (23) Etozeridine;
- 15 (24) Furethidine;
- 16 (25) Hydroxypethidine;
- 17 (26) Ketobemidone;
- 18 (27) Levomoramide;
- 19 (28) Levophenacymorphan;
- 20 (29) Morpheridine;
- 21 (30) Noracymethadol;
- 22 (31) Norlevorphanol;
- 23 (32) Normethadone;
- 24 (33) Norpipanone;
- 25 (34) Phenadoxone;
- 26 (35) Phenampromide;
- 27 (36) Phenomorphan;
- 28 (37) Phenoperidine;
- 29 (38) Piritramide;
- 30 (39) Proheptazine;
- 31 (40) Properidine;

- 1 (41) Propiram;
- 2 (42) Racemoramide;
- 3 (43) Trimeperidine;
- 4 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
- 5 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
- 6 piperidine;
- 7 (45) Tilidine;
- 8 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
- 9 phenylpropanamide, its optical and geometric isomers, salts, and salts of
- 10 isomers;
- 11 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
- 12 isomers, salts, and salts of isomers;
- 13 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
- 14 optical isomers, salts, and salts of isomers;
- 15 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
- 16 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
- 17 isomers;
- 18 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
- 19 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
- 20 of isomers;
- 21 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
- 22 its optical isomers, salts, and salts of isomers;
- 23 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
- 24 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
- 25 of isomers;
- 26 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
- 27 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
- 28 geometric isomers, salts, and salts of isomers;
- 29 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
- 30 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
- 31 salts, and salts of isomers;

- 1 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
2 (thenylfentanyl), its optical isomers, salts, and salts of isomers;  
3 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-  
4 propanamide, its optical isomers, salts, and salts of isomers;  
5 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-  
6 piperidinyl)propanamide, its optical isomers, salts, and salts of  
7 isomers;  
8 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
9 methylbenzamide;  
10 (59) 4-Fluoroisobutyryl Fentanyl;  
11 (60) Acetyl Fentanyl;  
12 (61) Acyrloylfentanyl;  
13 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]  
14 benzamide;  
15 (63) Butyryl fentanyl;  
16 (64) Cyclopentyl fentanyl;  
17 (65) Cyclopropyl fentanyl;  
18 (66) Furanyl fentanyl;  
19 (67) Isobutyryl fentanyl;  
20 (68) Isotonitazene;  
21 (69) Methoxyacetyl fentanyl;  
22 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;  
23 (71) Tetrahydrofuranyl fentanyl;  
24 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-  
25 yl) propionamide;  
26 (73) Ocfentanil;  
27 (74) Ortho-Fluorofentanyl;  
28 (75) Para-chloroisobutyryl fentanyl;  
29 (76) Para-Fluorobutyryl Fentanyl;  
30 (77) Valeryl fentanyl;  
31 (78) Phenyl Fentanyl;

- 1 (79) Para-Methylfentanyl;  
2 (80) Thiofuranyl Fentanyl;  
3 (81) Beta-methyl Fentanyl;  
4 (82) Beta'-Phenyl Fentanyl;  
5 (83) Crotonyl Fentanyl;  
6 (84) 2'-Fluoro Ortho-Fluorofentanyl;  
7 (85) 4'-Methyl Acetyl Fentanyl;  
8 (86) Ortho-Fluorobutyryl Fentanyl;  
9 (87) Ortho-Methyl Acetylfentanyl;  
10 (88) Ortho-Methyl Methoxyacetyl Fentanyl;  
11 (89) Ortho-Fluoroacryl Fentanyl;  
12 (90) Fentanyl Carbamate;  
13 (91) Ortho-Fluoroisobutyryl Fentanyl;  
14 (92) Para-Fluoro Furanyl Fentanyl;  
15 (93) Para-Methoxybutyryl Fentanyl;~~and~~  
16 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)  
17 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and -  
18 (95) Fentanyl-related substances, their isomers, esters, ethers,  
19 salts and salts of isomers, esters, and ethers. Unless specifically  
20 excepted, listed in another schedule, or specifically named in this  
21 schedule, this includes any substance that is structurally related to  
22 fentanyl by one or more of the following modifications:  
23 (A) Replacement of the phenyl portion of the phenethyl group by any  
24 monocycle, whether or not further substituted in or on the monocycle;  
25 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,  
26 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;  
27 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,  
28 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;  
29 (D) Replacement of the aniline ring with any aromatic monocycle  
30 whether or not further substituted in or on the aromatic monocycle; or  
31 (E) Replacement of the N-propionyl group by another acyl group.

1 (b) Any of the following opium derivatives, their salts, isomers,  
2 and salts of isomers, unless specifically excepted, whenever the  
3 existence of such salts, isomers, and salts of isomers is possible within  
4 the specific chemical designation:

- 5 (1) Acetorphine;
- 6 (2) Acetyldihydrocodeine;
- 7 (3) Benzylmorphine;
- 8 (4) Codeine methylbromide;
- 9 (5) Codeine-N-Oxide;
- 10 (6) Cyprenorphine;
- 11 (7) Desomorphine;
- 12 (8) Dihydromorphine;
- 13 (9) Drotebanol;
- 14 (10) Etorphine, except hydrochloride salt;
- 15 (11) Heroin;
- 16 (12) Hydromorphanol;
- 17 (13) Methyldesorphine;
- 18 (14) Methyldihydromorphine;
- 19 (15) Morphine methylbromide;
- 20 (16) Morphine methylsulfonate;
- 21 (17) Morphine-N-Oxide;
- 22 (18) Myrophine;
- 23 (19) Nicocodeine;
- 24 (20) Nicomorphine;
- 25 (21) Normorphine;
- 26 (22) Pholcodine; and
- 27 (23) Thebacon.

28 (c) Any material, compound, mixture, or preparation which contains  
29 any quantity of the following hallucinogenic substances, their salts,  
30 isomers, and salts of isomers, unless specifically excepted, whenever the  
31 existence of such salts, isomers, and salts of isomers is possible within

1 the specific chemical designation, and, for purposes of this subdivision  
2 only, isomer shall include the optical, position, and geometric isomers:

3 (1) Bufotenine. Trade and other names shall include, but are not  
4 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-  
5 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-  
6 dimethyltryptamine; and mappine;

7 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall  
8 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-  
9 methylphenethylamine; and 4-bromo-2,5-DMA;

10 (3) 4-methoxyamphetamine. Trade and other names shall include, but  
11 are not limited to: 4-methoxy-alpha-methylphenethylamine; and  
12 paramethoxyamphetamine, PMA;

13 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall  
14 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-  
15 methylphenethylamine; DOM; and STP;

16 (5) Para-methoxymethamphetamine. Trade and other names shall  
17 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-  
18 amine, PMMA, and 4-MMA;

19 (6) Ibogaine. Trade and other names shall include, but are not  
20 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-  
21 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe  
22 iboga;

23 (7) Lysergic acid diethylamide;

24 (8) Marijuana;

25 (9) Mescaline;

26 (10) Methoxetamine (MXE);

27 (11) (10) Peyote. Peyote shall mean all parts of the plant presently  
28 classified botanically as *Lophophora williamsii* Lemaire, whether growing  
29 or not, the seeds thereof, any extract from any part of such plant, and  
30 every compound, manufacture, salts, derivative, mixture, or preparation  
31 of such plant or its seeds or extracts;

1           (12) ~~(11)~~ Psilocybin;

2           (13) ~~(12)~~ Psilocyn;

3           (14) ~~(13)~~ Tetrahydrocannabinols, including, but not limited to,

4 synthetic equivalents of the substances contained in the plant or in the

5 resinous extractives of cannabis, sp. or synthetic substances,

6 derivatives, and their isomers with similar chemical structure and

7 pharmacological activity such as the following: Delta 1 cis or trans

8 tetrahydrocannabinol and their optical isomers, excluding dronabinol in a

9 drug product approved by the federal Food and Drug Administration; Delta

10 6 cis or trans tetrahydrocannabinol and their optical isomers; and Delta

11 3,4 cis or trans tetrahydrocannabinol and its optical isomers. Since

12 nomenclature of these substances is not internationally standardized,

13 compounds of these structures shall be included regardless of the

14 numerical designation of atomic positions covered. Tetrahydrocannabinols

15 does not include cannabidiol contained in a drug product approved by the

16 federal Food and Drug Administration;

17           (15) ~~(14)~~ N-ethyl-3-piperidyl benzilate;

18           (16) ~~(15)~~ N-methyl-3-piperidyl benzilate;

19           (17) ~~(16)~~ Thiophene analog of phencyclidine. Trade and other names

20 shall include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-

21 piperidine; 2-thienyl analog of phencyclidine; TPCP; and TCP;

22           (18) ~~(17)~~ Hashish or concentrated cannabis;

23           (19) ~~(18)~~ Parahexyl. Trade and other names shall include, but are

24 not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

25 dibenzo(b,d)pyran; and Synhexyl;

26           (20) ~~(19)~~ Ethylamine analog of phencyclidine. Trade and other names

27 shall include, but are not limited to: N-ethyl-1-phenylcyclohexylamine;

28 (1-phenylcyclohexyl)ethylamine;           N-(1-phenylcyclohexyl)ethylamine;

29 cyclohexamine; and PCE;

30           (21) ~~(20)~~ Pyrrolidine analog of phencyclidine. Trade and other names

31 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-

1 pyrrolidine; PCPy; and PHP;

2 (22) ~~(21)~~ Alpha-ethyltryptamine. Some trade or other names:  
3 etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)  
4 indole; alpha-ET; and AET;

5 (23) ~~(22)~~ 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

6 (24) ~~(23)~~ 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

7 (25) ~~(24)~~ Alpha-methyltryptamine, which is also known as AMT;

8 (26) ~~(25)~~ Salvia divinorum or Salvinorin A. Salvia divinorum or  
9 Salvinorin A includes all parts of the plant presently classified  
10 botanically as Salvia divinorum, whether growing or not, the seeds  
11 thereof, any extract from any part of such plant, and every compound,  
12 manufacture, derivative, mixture, or preparation of such plant, its  
13 seeds, or its extracts, including salts, isomers, and salts of isomers  
14 whenever the existence of such salts, isomers, and salts of isomers is  
15 possible within the specific chemical designation;

16 (27) ~~(26)~~ Any material, compound, mixture, or preparation containing  
17 any quantity of synthetically produced cannabinoids as listed in  
18 subdivisions (A) through (L) of this subdivision, including their salts,  
19 isomers, salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic  
20 analogs, unless specifically excepted elsewhere in this section. Since  
21 nomenclature of these synthetically produced cannabinoids is not  
22 internationally standardized and may continually evolve, these structures  
23 or compounds of these structures shall be included under this  
24 subdivision, regardless of their specific numerical designation of atomic  
25 positions covered, so long as it can be determined through a recognized  
26 method of scientific testing or analysis that the substance contains  
27 properties that fit within one or more of the following categories:

28 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally  
29 contained in a plant of the genus cannabis (cannabis plant), as well as  
30 synthetic equivalents of the substances contained in the plant, or in the  
31 resinous extractives of cannabis, sp. and/or synthetic substances,

1 derivatives, and their isomers with similar chemical structure and  
2 pharmacological activity such as the following: Delta 1 cis or trans  
3 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans  
4 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans  
5 tetrahydrocannabinol, and its optical isomers. This subdivision does not  
6 include cannabidiol contained in a drug product approved by the federal  
7 Food and Drug Administration;

8 (B) Naphthoylindoles: Any compound containing a 3-(1-  
9 naphthoyl)indole structure with substitution at the nitrogen atom of the  
10 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
11 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
12 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
13 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
14 tetrahydropyranylmethyl group, whether or not further substituted in or  
15 on any of the listed ring systems to any extent;

16 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-  
17 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom  
18 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
19 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
20 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
21 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
22 tetrahydropyranylmethyl group, whether or not further substituted in or  
23 on any of the listed ring systems to any extent;

24 (D) Naphthoylpyrroles: Any compound containing a 3-(1-  
25 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the  
26 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
27 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
28 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
29 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
30 tetrahydropyranylmethyl group, whether or not further substituted in or  
31 on any of the listed ring systems to any extent;

1 (E) Naphthylideneindenes: Any compound containing a  
2 naphthylideneindene structure with substitution at the 3-position of the  
3 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
4 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
5 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
7 tetrahydropyranylmethyl group, whether or not further substituted in or  
8 on any of the listed ring systems to any extent;

9 (F) Phenylacetylindoles: Any compound containing a 3-  
10 phenylacetylindole structure with substitution at the nitrogen atom of  
11 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
12 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
13 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
15 tetrahydropyranylmethyl group, whether or not further substituted in or  
16 on any of the listed ring systems to any extent;

17 (G) Cyclohexylphenols: Any compound containing a 2-(3-  
18 hydroxycyclohexyl)phenol structure with substitution at the 5-position of  
19 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
20 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
21 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
22 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
23 tetrahydropyranylmethyl group, whether or not substituted in or on any of  
24 the listed ring systems to any extent;

25 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole  
26 structure with substitution at the nitrogen atom of the indole ring by an  
27 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,  
28 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-  
29 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
30 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
31 further substituted in or on any of the listed ring systems to any

1 extent;

2 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole  
3 structure with substitution at the nitrogen atom of the indole ring by an  
4 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,  
5 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
6 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
7 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
8 further substituted in or on any of the listed ring systems to any  
9 extent;

10 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-  
11 tetramethylcyclopropanoylindole structure with substitution at the  
12 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
13 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
14 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
15 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
16 tetrahydropyranylmethyl group, whether or not further substituted in or  
17 on any of the listed ring systems to any extent;

18 (K) Indole carboxamides: Any compound containing a 1-indole-3-  
19 carboxamide structure with substitution at the nitrogen atom of the  
20 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
21 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
22 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
23 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
24 tetrahydropyranylmethyl group, substitution at the carboxamide group by  
25 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
26 phenyl, aminoalkyl group, or quinolinyl group, whether or not further  
27 substituted in or on any of the listed ring systems to any extent or to  
28 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or  
29 propionaldehyde groups to any extent;

30 (L) Indole carboxylates: Any compound containing a 1-indole-3-  
31 carboxylate structure with substitution at the nitrogen atom of the

1 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
2 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
3 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
5 tetrahydropyranylmethyl group, substitution at the carboxylate group by  
6 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
7 phenyl, aminoalkyl group, or quinolinyl group, whether or not further  
8 substituted in or on any of the listed ring systems to any extent or to  
9 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or  
10 propionaldehyde groups to any extent; and

11 (M) Any nonnaturally occurring substance, chemical compound,  
12 mixture, or preparation, not specifically listed elsewhere in these  
13 schedules and which is not approved for human consumption by the federal  
14 Food and Drug Administration, containing or constituting a cannabinoid  
15 receptor agonist as defined in section 28-401;

16 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-  
17 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,  
18 and salts of isomers, esters, and ethers, whenever the existence of such  
19 isomers, esters, ethers, and salts is possible within the specific  
20 chemical designation;

21 (29) ~~(27)~~ Any material, compound, mixture, or preparation containing  
22 any quantity of a substituted phenethylamine as listed in subdivisions  
23 (A) through (C) of this subdivision, unless specifically excepted, listed  
24 in another schedule, or specifically named in this schedule, that is  
25 structurally derived from phenylethan-2-amine by substitution on the  
26 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a  
27 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by  
28 substitution with one alkoxy and either one fused furan, tetrahydrofuran,  
29 or tetrahydropyran ring system; or by substitution with two fused ring  
30 systems from any combination of the furan, tetrahydrofuran, or  
31 tetrahydropyran ring systems, whether or not the compound is further

1 modified in any of the following ways:

2 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,  
3 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-  
4 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen  
5 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,  
6 and including, but not limited to:

7 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known  
8 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

9 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known  
10 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

11 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known  
12 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

13 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H  
14 or 2,5-Dimethoxyphenethylamine;

15 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as  
16 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;

17 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known  
18 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;

19 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also  
20 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;

21 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
22 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;

23 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
24 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;

25 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known  
26 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;

27 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also  
28 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;

29 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also  
30 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;

31 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also

- 1 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 2 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
- 3 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 4 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
- 5 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
- 6 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 7 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
- 8 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
- 9 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 10 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
- 11 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
- 12 methoxybenzyl)phenethylamine;
- 13 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
- 14 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
- 15 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 16 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
- 17 which is also known as 2CB-5-hemiFLY;
- 18 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
- 19 yl)ethanamine, which is also known as 2C-B-FLY;
- 20 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
- 21 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 22 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
- 23 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
- 24 NBOMe;
- 25 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
- 26 which is also known as bromo-benzodifuranylisopropylamine or bromo-
- 27 dragonFLY;
- 28 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
- 29 is also known as 2C-INBOH or 25I-NBOH;
- 30 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
- 31 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;

1 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known  
2 as 5-APDB;

3 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also  
4 known as 6-APDB;

5 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-  
6 dimethoxy-a-methylphenethylamine; 2, 5-DMA;

7 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;

8 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also  
9 known as 2C-T-7;

10 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;

11 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as  
12 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;

13 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;

14 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as  
15 MDMA;

16 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known  
17 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;

18 (xxxvii) 3,4,5-trimethoxy amphetamine; and

19 (xxxviii) n-hydroxy-3,4-Methylenedioxy-N-Hydroxyamphetamine, which  
20 is also known as N-hydroxyMDA;

21 (30) ~~(28)~~ Any material, compound, mixture, or preparation containing  
22 any quantity of a substituted tryptamine unless specifically excepted,  
23 listed in another schedule, or specifically named in this schedule, that  
24 is structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also  
25 known as tryptamine, by mono- or di-substitution of the amine nitrogen  
26 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom  
27 in a cyclic structure whether or not the compound is further substituted  
28 at the alpha position with an alkyl group or whether or not further  
29 substituted on the indole ring to any extent with any alkyl, alkoxy,  
30 halo, hydroxyl, or acetoxy groups, and including, but not limited to:

31 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-

1 DALT;

2 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-  
3 DMT or OAcetylpsilocin;

4 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-  
5 HO-MET;

6 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-  
7 HO-DIPT;

8 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as  
9 5-MeOMiPT;

10 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-  
11 DMT;

12 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-  
13 MeO-DiPT;

14 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,  
15 DET; and

16 (I) Dimethyltryptamine, which is also known as DMT; and

17 ~~(31)(A)~~ ~~(29)(A)~~ Any substance containing any quantity of the  
18 following materials, compounds, mixtures, or structures:

19 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methytlone;

20 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;

21 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

22 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

23 (v) Fluoromethcathinone, or FMC;

24 (vi) Naphthylpyrovalerone, or naphyrone; or

25 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or  
26 butylone; or

27 (B) Unless listed in another schedule, any substance which contains  
28 any quantity of any material, compound, mixture, or structure, other than  
29 bupropion, that is structurally derived by any means from 2-  
30 aminopropan-1-one by substitution at the 1-position with either phenyl,  
31 naphthyl, or thiophene ring systems, whether or not the compound is

1 further modified in any of the following ways:

2 (i) Substitution in the ring system to any extent with alkyl,  
3 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,  
4 whether or not further substituted in the ring system by one or more  
5 other univalent substituents;

6 (ii) Substitution at the 3-position with an acyclic alkyl  
7 substituent; or

8 (iii) Substitution at the 2-amino nitrogen atom with alkyl or  
9 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic  
10 structure.

11 (d) Unless specifically excepted or unless listed in another  
12 schedule, any material, compound, mixture, or preparation which contains  
13 any quantity of the following substances having a depressant effect on  
14 the central nervous system, including its salts, isomers, and salts of  
15 isomers whenever the existence of such salts, isomers, and salts of  
16 isomers is possible within the specific chemical designation:

17 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-  
18 yl)amino]heptanoic acid, including its salts, isomers, and salts of  
19 isomers;

20 (2) ~~(1)~~ Mecloqualone;

21 (3) ~~(2)~~ Methaqualone; and

22 (4) ~~(3)~~ Gamma-Hydroxybutyric Acid. Some other names include: GHB;  
23 Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium  
24 Oxybate; and Sodium Oxybutyrate.

25 (e) Unless specifically excepted or unless listed in another  
26 schedule, any material, compound, mixture, or preparation which contains  
27 any quantity of the following substances having a stimulant effect on the  
28 central nervous system, including its salts, isomers, and salts of  
29 isomers:

30 (1) Fenethylamine;

31 (2) N-ethylamphetamine;

1 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-  
2 dihydro-5-phenyl-2-oxazolamine;

3 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-  
4 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

5 (5) Methcathinone, its salts, optical isomers, and salts of optical  
6 isomers. Some other names: 2-(methylamino)-propiofenone; alpha-  
7 (methylamino)propiofenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-  
8 N-methylaminopropiofenone; methylcathinone; monomethylpropion;  
9 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;

10 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-  
11 phenyl-2-oxazolamine;

12 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;  
13 and N,N-alpha-trimethylphenethylamine;

14 (8) Benzylpiperazine, 1-benzylpiperazine; ~~and~~

15 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-  
16 methyl-5-(4-methylphenyl)-2-oxazolamine); ~~and~~ -

17 (10) N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-  
18 ium-5-yl)carbamimidate), including its salts, isomers, and salts of  
19 isomers.

20 (f) Any controlled substance analogue to the extent intended for  
21 human consumption.

22 Schedule II

23 (a) Any of the following substances except those narcotic drugs  
24 listed in other schedules whether produced directly or indirectly by  
25 extraction from substances of vegetable origin, independently by means of  
26 chemical synthesis, or by combination of extraction and chemical  
27 synthesis:

28 (1) Opium and opiate, and any salt, compound, derivative, or  
29 preparation of opium or opiate, excluding apomorphine, buprenorphine,  
30 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,  
31 naloxone, and naltrexone and their salts, but including the following:

- 1 (A) Raw opium;
- 2 (B) Opium extracts;
- 3 (C) Opium fluid;
- 4 (D) Powdered opium;
- 5 (E) Granulated opium;
- 6 (F) Tincture of opium;
- 7 (G) Codeine;
- 8 (H) Ethylmorphine;
- 9 (I) Etorphine hydrochloride;
- 10 (J) Hydrocodone;
- 11 (K) Hydromorphone;
- 12 (L) Metopon;
- 13 (M) Morphine;
- 14 (N) Oxycodone;
- 15 (O) Oxymorphone;
- 16 (P) Oripavine;
- 17 (Q) Thebaine; and
- 18 (R) Dihydroetorphine;
- 19 (2) Any salt, compound, derivative, or preparation thereof which is
- 20 chemically equivalent to or identical with any of the substances referred
- 21 to in subdivision (1) of this subdivision, except that these substances
- 22 shall not include the isoquinoline alkaloids of opium;
- 23 (3) Opium poppy and poppy straw;
- 24 (4) Coca leaves and any salt, compound, derivative, or preparation
- 25 of coca leaves, and any salt, compound, derivative, or preparation
- 26 thereof which is chemically equivalent to or identical with any of these
- 27 substances, including cocaine or ecgonine and its salts, optical isomers,
- 28 and salts of optical isomers, except that the substances shall not
- 29 include decocainized coca leaves or extractions which do not contain
- 30 cocaine or ecgonine; and
- 31 (5) Concentrate of poppy straw, the crude extract of poppy straw in

1 either liquid, solid, or powder form which contains the phenanthrene  
2 alkaloids of the opium poppy.

3 (b) Unless specifically excepted or unless in another schedule any  
4 of the following opiates, including their isomers, esters, ethers, salts,  
5 and salts of their isomers, esters, and ethers whenever the existence of  
6 such isomers, esters, ethers, and salts is possible within the specific  
7 chemical designation, dextrorphan excepted:

- 8 (1) Alphaprodine;
- 9 (2) Anileridine;
- 10 (3) Bezitramide;
- 11 (4) Diphenoxylate;
- 12 (5) Fentanyl;
- 13 (6) Isomethadone;
- 14 (7) Levomethorphan;
- 15 (8) Levorphanol;
- 16 (9) Metazocine;
- 17 (10) Methadone;
- 18 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl  
19 butane;
- 20 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-  
21 diphenylpropane-carboxylic acid;
- 22 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
- 23 (14) Oliceridine;
- 24 (15) Pethidine or meperidine;
- 25 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 26 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-  
27 carboxylate;
- 28 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-  
29 carboxylic acid;
- 30 (19) Phenazocine;
- 31 (20) Piminodine;

- 1 (21) Racemethorphan;
- 2 (22) Racemorphan;
- 3 (23) Dihydrocodeine;
- 4 (24) Bulk Propoxyphene in nondosage forms;
- 5 (25) Sufentanil;
- 6 (26) Alfentanil;
- 7 (27) Levo-alphaacetylmethadol which is also known as levo-alpha-
- 8 acetylmethadol, levomethadyl acetate, and LAAM;
- 9 (28) Carfentanil;
- 10 (29) Remifentanil;
- 11 (30) Tapentadol; and
- 12 (31) Thiafentanil.

13 (c) Any material, compound, mixture, or preparation which contains  
14 any quantity of the following substances having a potential for abuse  
15 associated with a stimulant effect on the central nervous system:

- 16 (1) Amphetamine, its salts, optical isomers, and salts of its  
17 optical isomers;
- 18 (2) Phenmetrazine and its salts;
- 19 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
- 20 (4) Methylphenidate; and
- 21 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.

22 (d) Any material, compound, mixture, or preparation which contains  
23 any quantity of the following substances having a potential for abuse  
24 associated with a depressant effect on the central nervous system,  
25 including their salts, isomers, and salts of isomers whenever the  
26 existence of such salts, isomers, and salts of isomers is possible within  
27 the specific chemical designations:

- 28 (1) Amobarbital;
- 29 (2) Secobarbital;
- 30 (3) Pentobarbital;
- 31 (4) Phencyclidine; and

1 (5) Glutethimide.

2 (e) Hallucinogenic substances known as:

3 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-  
4 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-  
5 dibenzo(b,d)pyran-9-one; and

6 (2) Dronabinol in an oral solution in a drug product approved by the  
7 federal Food and Drug Administration.

8 (f) Unless specifically excepted or unless listed in another  
9 schedule, any material, compound, mixture, or preparation which contains  
10 any quantity of the following substances:

11 (1) Immediate precursor to amphetamine and methamphetamine:  
12 Phenylacetone. Trade and other names shall include, but are not limited  
13 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
14 ketone;

15 (2) Immediate precursors to phencyclidine, PCP:

16 (A) 1-phenylcyclohexylamine; or

17 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

18 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine  
19 (ANPP).

20 Schedule III

21 (a) Any material, compound, mixture, or preparation which contains  
22 any quantity of the following substances having a potential for abuse  
23 associated with a stimulant effect on the central nervous system,  
24 including their salts, isomers, whether optical, position, or geometric,  
25 and salts of such isomers whenever the existence of such salts, isomers,  
26 and salts of isomers is possible within the specific chemical  
27 designation:

28 (1) Benzphetamine;

29 (2) Chlorphentermine;

30 (3) Clortermine; and

31 (4) Phendimetrazine.

1 (b) Any material, compound, mixture, or preparation which contains  
2 any quantity of the following substances having a potential for abuse  
3 associated with a depressant effect on the central nervous system:

4 (1) Any substance which contains any quantity of a derivative of  
5 barbituric acid or any salt of a derivative of barbituric acid, except  
6 those substances which are specifically listed in other schedules of this  
7 section;

8 (2) Aprobarbital;

9 (3) Butabarbital;

10 (4) Butalbital;

11 (5) Butethal;

12 (6) Butobarbital;

13 (7) Chlorhexadol;

14 (8) Embutramide;

15 (9) Lysergic acid;

16 (10) Lysergic acid amide;

17 (11) Methyprylon;

18 (12) Perampanel;

19 (13) Secbutabarbital;

20 (14) Sulfondiethylmethane;

21 (15) Sulfonethylmethane;

22 (16) Sulfonmethane;

23 (17) Nalorphine;

24 (18) Talbutal;

25 (19) Thiamylal;

26 (20) Thiopental;

27 (21) Vinbarbital;

28 (22) Any compound, mixture, or preparation containing amobarbital,  
29 secobarbital, pentobarbital, or any salt thereof and one or more other  
30 active medicinal ingredients which are not listed in any schedule;

31 (23) Any suppository dosage form containing amobarbital,

1 secobarbital, pentobarbital, or any salt of any of these drugs and  
2 approved by the federal Food and Drug Administration for marketing only  
3 as a suppository;

4 (24) Any drug product containing gamma-hydroxybutyric acid,  
5 including its salts, isomers, and salts of isomers, for which an  
6 application is approved under section 505 of the Federal Food, Drug, and  
7 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

8 (25) Ketamine, its salts, isomers, and salts of isomers. Some other  
9 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-  
10 cyclohexanone; and

11 (26) Tiletamine and zolazepam or any salt thereof. Trade or other  
12 names for a tiletamine-zolazepam combination product shall include, but  
13 are not limited to: telazol. Trade or other names for tiletamine shall  
14 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-  
15 cyclohexanone. Trade or other names for zolazepam shall include, but are  
16 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-  
17 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.

18 (c) Unless specifically excepted or unless listed in another  
19 schedule:

20 (1) Any material, compound, mixture, or preparation containing  
21 limited quantities of any of the following narcotic drugs, or any salts  
22 calculated as the free anhydrous base or alkaloid, in limited quantities  
23 as set forth below:

24 (A) Not more than one and eight-tenths grams of codeine per one  
25 hundred milliliters or not more than ninety milligrams per dosage unit,  
26 with an equal or greater quantity of an isoquinoline alkaloid of opium;

27 (B) Not more than one and eight-tenths grams of codeine per one  
28 hundred milliliters or not more than ninety milligrams per dosage unit,  
29 with one or more active, nonnarcotic ingredients in recognized  
30 therapeutic amounts;

31 (C) Not more than one and eight-tenths grams of dihydrocodeine per

1 one hundred milliliters or not more than ninety milligrams per dosage  
2 unit, with one or more active, nonnarcotic ingredients in recognized  
3 therapeutic amounts;

4 (D) Not more than three hundred milligrams of ethylmorphine per one  
5 hundred milliliters or not more than fifteen milligrams per dosage unit,  
6 with one or more active, nonnarcotic ingredients in recognized  
7 therapeutic amounts;

8 (E) Not more than five hundred milligrams of opium per one hundred  
9 milliliters or per one hundred grams, or not more than twenty-five  
10 milligrams per dosage unit, with one or more active, nonnarcotic  
11 ingredients in recognized therapeutic amounts; and

12 (F) Not more than fifty milligrams of morphine per one hundred  
13 milliliters or per one hundred grams with one or more active, nonnarcotic  
14 ingredients in recognized therapeutic amounts; and

15 (2) Any material, compound, mixture, or preparation containing any  
16 of the following narcotic drug or its salts, as set forth below:

17 (A) Buprenorphine.

18 (d) Unless contained on the list of exempt anabolic steroids of the  
19 Drug Enforcement Administration of the United States Department of  
20 Justice as the list existed on January 31, 2022 ~~2021~~, any anabolic  
21 steroid, which shall include any material, compound, mixture, or  
22 preparation containing any quantity of the following substances,  
23 including its salts, isomers, and salts of isomers whenever the existence  
24 of such salts of isomers is possible within the specific chemical  
25 designation:

26 (1) 3-beta,17-dihydroxy-5a-androstane;

27 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;

28 (3) 5-alpha-androstan-3,17-dione;

29 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-  
30 ene);

31 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-

- 1 ene);
- 2 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
- 3 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
- 4 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
- 5 (9) 4-androstenedione (androst-4-en-3,17-dione);
- 6 (10) 5-androstenedione (androst-5-en-3,17-dione);
- 7 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
- 8 hydroxyandrost-4-en-3-one);
- 9 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
- 10 (13) Boldione (androsta-1,4-diene-3,17-3-one);
- 11 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
- 12 en-3-one);
- 13 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
- 14 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
- 15 alpha-methyl-androst-1,4-dien-3-one);
- 16 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 17 en-17-beta-ol) (a.k.a. 'madol');
- 18 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 19 hydroxy-5-alpha-androst-1-en-3-one);
- 20 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
- 21 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 22 androstan-3-one);
- 23 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
- 24 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 25 dihydroxyandrost-4-en-3-one);
- 26 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-
- 27 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
- 28 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostan[2,3-c]-
- 29 furazan);
- 30 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
- 31 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);

- 1 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-  
2 one);
- 3 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-  
4 one);
- 5 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-  
6 one);
- 7 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-  
8 dien-3-one);
- 9 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-  
10 ene);
- 11 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-  
12 beta-ol-3-one);
- 13 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-  
14 one);
- 15 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
- 16 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
- 17 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
- 18 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-  
19 hydroxy-17-beta-hydroxyestr-4-en-3-one);
- 20 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-  
21 dien-3-one);
- 22 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-  
23 trien-3-one);
- 24 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-  
25 en-3-one);
- 26 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-  
27 en-3-one);
- 28 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-  
29 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-  
30 methyl-1-testosterone');
- 31 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);

- 1 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
- 2 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
- 3 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
- 4 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
- 5 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
- 6 dione);
- 7 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 8 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 9 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
- 10 en-3-one);
- 11 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
- 12 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
- 13 one);
- 14 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
- 15 one);
- 16 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
- 17 androstan-3-one);
- 18 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
- 19 en-3-one);
- 20 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
- 21 hydroxy-[5-alpha]-androstan-3-one);
- 22 (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-
- 23 c]pyrazole);
- 24 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
- 25 androst-2-eno[3,2-c]-pyrazole);
- 26 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
- 27 one);
- 28 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
- 29 oic acid lactone);
- 30 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
- 31 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-

- 1 hydroxygon-4,9,11-trien-3-one);
- 2 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
- 3 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
- 4 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
- 5 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
- 6 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
- 7 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
- 8 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
- 9 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
- 10 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
- 11 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
- 12 beta-ol;
- 13 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
- 14 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
- 15 dione;
- 16 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
- 17 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
- 18 (78) 4-hydroxy-androst-4-ene-3,17-dione;
- 19 (79) 5 alpha-Androstan-3,6,17-trione;
- 20 (80) 6-bromo-androst-1,4-diene-3,17-dione;
- 21 (81) 6-bromo-androstan-3,17-dione;
- 22 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
- 23 (83) Delta 1-dihydrotestosterone;
- 24 (84) Estra-4,9,11-triene-3,17-dione; and
- 25 (85) Any salt, ester, or ether of a drug or substance described or
- 26 listed in this subdivision if the salt, ester, or ether promotes muscle
- 27 growth.

28 (e) Hallucinogenic substances known as:

- 29 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
- 30 gelatin capsule in a drug product approved by the federal Food and Drug
- 31 Administration. Some other names for dronabinol are (6aR-

1 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
2 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

3 Schedule IV

4 (a) Any material, compound, mixture, or preparation which contains  
5 any quantity of the following substances, including their salts, isomers,  
6 and salts of isomers whenever the existence of such salts, isomers, and  
7 salts of isomers is possible within the specific chemical designation:

8 (1) Barbital;

9 (2) Chloral betaine;

10 (3) Chloral hydrate;

11 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide  
12 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and  
13 water soluble esterified estrogens);

14 (5) Clonazepam;

15 (6) Clorazepate;

16 (7) Daridorexant;

17 (8) (7) Diazepam;

18 (9) (8) Ethchlorvynol;

19 (10) (9) Ethinamate;

20 (11) (10) Flurazepam;

21 (12) (11) Mebutamate;

22 (13) (12) Meprobamate;

23 (14) (13) Methohexital;

24 (15) (14) Methylphenobarbital;

25 (16) (15) Oxazepam;

26 (17) (16) Paraldehyde;

27 (18) (17) Petrichloral;

28 (19) (18) Phenobarbital;

29 (20) (19) Prazepam;

30 (21) (20) Alprazolam;

31 (22) (21) Bromazepam;

- 1        (~~23~~) (~~22~~) Camazepam;
- 2        (~~24~~) (~~23~~) Clobazam;
- 3        (~~25~~) (~~24~~) Clotiazepam;
- 4        (~~26~~) (~~25~~) Cloxazolam;
- 5        (~~27~~) (~~26~~) Delorazepam;
- 6        (~~28~~) (~~27~~) Estazolam;
- 7        (~~29~~) (~~28~~) Ethyl loflazepate;
- 8        (~~30~~) (~~29~~) Fludiazepam;
- 9        (~~31~~) (~~30~~) Flunitrazepam;
- 10       (~~32~~) (~~31~~) Halazepam;
- 11       (~~33~~) (~~32~~) Haloxazolam;
- 12       (~~34~~) (~~33~~) Ketazolam;
- 13       (~~35~~) (~~34~~) Loprazolam;
- 14       (~~36~~) (~~35~~) Lorazepam;
- 15       (~~37~~) (~~36~~) Lormetazepam;
- 16       (~~38~~) (~~37~~) Medazepam;
- 17       (~~39~~) (~~38~~) Nimetazepam;
- 18       (~~40~~) (~~39~~) Nitrazepam;
- 19       (~~41~~) (~~40~~) Nordiazepam;
- 20       (~~42~~) (~~41~~) Oxazolam;
- 21       (~~43~~) (~~42~~) Pinazepam;
- 22       (~~44~~) (~~43~~) Temazepam;
- 23       (~~45~~) (~~44~~) Tetrazepam;
- 24       (~~46~~) (~~45~~) Triazolam;
- 25       (~~47~~) (~~46~~) Midazolam;
- 26       (~~48~~) (~~47~~) Quazepam;
- 27       (~~49~~) (~~48~~) Zolpidem;
- 28       (~~50~~) (~~49~~) Dichloralphenazone;
- 29       (~~51~~) (~~50~~) Zaleplon;
- 30       (~~52~~) (~~51~~) Zopiclone;
- 31       (~~53~~) (~~52~~) Fospropofol;

- 1           (54) ~~(53)~~ Alfaxalone;
- 2           (55) ~~(54)~~ Suvorexant;
- 3           (56) ~~(55)~~ Carisoprodol;
- 4           (57) ~~(56)~~ Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
- 5           (58) ~~(57)~~ Lemborexant;
- 6           (59) ~~(58)~~ Solriamfetol; 2-amino-3-phenylpropyl carbamate;
- 7           (60) ~~(59)~~ Remimazolam; and
- 8           (61) ~~(60)~~ Serdexmethylphenidate.

9           (b) Any material, compound, mixture, or preparation which contains  
10 any quantity of the following substance, including its salts, isomers,  
11 whether optical, position, or geometric, and salts of such isomers,  
12 whenever the existence of such salts, isomers, and salts of isomers is  
13 possible: Fenfluramine.

14           (c) Unless specifically excepted or unless listed in another  
15 schedule, any material, compound, mixture, or preparation which contains  
16 any quantity of the following substances having a stimulant effect on the  
17 central nervous system, including their salts, isomers, whether optical,  
18 position, or geometric, and salts of such isomers whenever the existence  
19 of such salts, isomers, and salts of isomers is possible within the  
20 specific chemical designation:

- 21           (1) Diethylpropion;
- 22           (2) Phentermine;
- 23           (3) Pemoline, including organometallic complexes and chelates  
24 thereof;
- 25           (4) Mazindol;
- 26           (5) Pipradrol;
- 27           (6) SPA, ((-)-1-dimethylamino--1,2-diphenylethane);
- 28           (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
- 29           (8) Fencamfamin;
- 30           (9) Fenproporex;
- 31           (10) Mefenorex;

1 (11) Modafinil; and

2 (12) Sibutramine.

3 (d) Unless specifically excepted or unless listed in another  
4 schedule, any material, compound, mixture, or preparation which contains  
5 any quantity of the following narcotic drugs, or their salts or isomers  
6 calculated as the free anhydrous base or alkaloid, in limited quantities  
7 as set forth below:

8 (1) Propoxyphene in manufactured dosage forms;

9 (2) Not more than one milligram of difenoxin and not less than  
10 twenty-five micrograms of atropine sulfate per dosage unit; and

11 (3) 2-[[dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
12 salts, optical and geometric isomers, and salts of these isomers to  
13 include: Tramadol.

14 (e) Unless specifically excepted or unless listed in another  
15 schedule, any material, compound, mixture, or preparation which contains  
16 any quantity of the following substance, including its salts:

17 (1) Pentazocine; and

18 (2) Butorphanol (including its optical isomers).

19 (f) Any material, compound, mixture, or preparation which contains  
20 any quantity of the following substances, including its salts, isomers,  
21 and salts of such isomers, whenever the existence of such salts, isomers,  
22 and salts of isomers is possible: Lorcaserin.

23 (g)(1) Unless specifically excepted or unless listed in another  
24 schedule, any material, compound, mixture, or preparation which contains  
25 any quantity of the following substance, including its salts, optical  
26 isomers, and salts of such optical isomers: Ephedrine.

27 (2) The following drug products containing ephedrine, its salts,  
28 optical isomers, and salts of such optical isomers, are excepted from  
29 subdivision (g)(1) of Schedule IV if they (A) are stored behind a  
30 counter, in an area not accessible to customers, or in a locked case so  
31 that a customer needs assistance from an employee to access the drug

1 product; (B) are sold by a person, eighteen years of age or older, in the  
2 course of his or her employment to a customer eighteen years of age or  
3 older with the following restrictions: No customer shall be allowed to  
4 purchase, receive, or otherwise acquire more than three and six-tenths  
5 grams of ephedrine base during a twenty-four-hour period; no customer  
6 shall purchase, receive, or otherwise acquire more than nine grams of  
7 ephedrine base during a thirty-day period; and the customer shall display  
8 a valid driver's or operator's license, a Nebraska state identification  
9 card, a military identification card, an alien registration card, or a  
10 passport as proof of identification; (C) are labeled and marketed in a  
11 manner consistent with the pertinent OTC Tentative Final or Final  
12 Monograph; (D) are manufactured and distributed for legitimate medicinal  
13 use in a manner that reduces or eliminates the likelihood of abuse; and  
14 (E) are not marketed, advertised, or represented in any manner for the  
15 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or  
16 high, heightened sexual performance, or increased muscle mass:

- 17 (i) Primatene Tablets; and
- 18 (ii) Bronkaid Dual Action Caplets.

19 Schedule V

20 (a) Any compound, mixture, or preparation containing any of the  
21 following limited quantities of narcotic drugs or salts calculated as the  
22 free anhydrous base or alkaloid, which shall include one or more  
23 nonnarcotic active medicinal ingredients in sufficient proportion to  
24 confer upon the compound, mixture, or preparation valuable medicinal  
25 qualities other than those possessed by the narcotic drug alone:

- 26 (1) Not more than two hundred milligrams of codeine per one hundred  
27 milliliters or per one hundred grams;
- 28 (2) Not more than one hundred milligrams of dihydrocodeine per one  
29 hundred milliliters or per one hundred grams;
- 30 (3) Not more than one hundred milligrams of ethylmorphine per one  
31 hundred milliliters or per one hundred grams;

1 (4) Not more than two and five-tenths milligrams of diphenoxylate  
2 and not less than twenty-five micrograms of atropine sulfate per dosage  
3 unit;

4 (5) Not more than one hundred milligrams of opium per one hundred  
5 milliliters or per one hundred grams; and

6 (6) Not more than five-tenths milligram of difenoxin and not less  
7 than twenty-five micrograms of atropine sulfate per dosage unit.

8 (b) Unless specifically exempted or excluded or unless listed in  
9 another schedule, any material, compound, mixture, or preparation which  
10 contains any quantity of the following substances having a stimulant  
11 effect on the central nervous system, including its salts, isomers, and  
12 salts of isomers: Pyrovalerone.

13 (c) Unless specifically exempted or excluded or unless listed in  
14 another schedule, any material, compound, mixture, or preparation which  
15 contains any quantity of the following substances having a depressant  
16 effect on the central nervous system, including its salts, isomers, and  
17 salts of isomers:

18 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic  
19 acid ethyl ester);

20 (2) Ganaxolone;

21 (3) ~~(2)~~ Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-  
22 propionamide);

23 (4) ~~(3)~~ Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);

24 (5) ~~(4)~~ Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]  
25 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its  
26 salts;

27 (6) ~~(5)~~ Cenobamate; and

28 (7) ~~(6)~~ Lasmiditan.

29 Sec. 4. Section 28-416, Revised Statutes Cumulative Supplement,  
30 2022, is amended to read:

31 28-416 (1) Except as authorized by the Uniform Controlled Substances

1 Act, it shall be unlawful for any person knowingly or intentionally: (a)  
2 To manufacture, distribute, deliver, dispense, or possess with intent to  
3 manufacture, distribute, deliver, or dispense a controlled substance; or  
4 (b) to create, distribute, or possess with intent to distribute a  
5 counterfeit controlled substance.

6 (2) Except as provided in subsections (4), (5), (7), (8), (9), and  
7 (10) of this section, any person who violates subsection (1) of this  
8 section with respect to: (a) A controlled substance classified in  
9 Schedule I, II, or III of section 28-405 which is an exceptionally  
10 hazardous drug shall be guilty of a Class II felony; (b) any other  
11 controlled substance classified in Schedule I, II, or III of section  
12 28-405 shall be guilty of a Class IIA felony; or (c) a controlled  
13 substance classified in Schedule IV or V of section 28-405 shall be  
14 guilty of a Class IIIA felony.

15 (3) A person knowingly or intentionally possessing a controlled  
16 substance, except marijuana or any substance containing a quantifiable  
17 amount of the substances, chemicals, or compounds described, defined, or  
18 delineated in subdivision (c)(27) ~~(c)(26)~~ of Schedule I of section  
19 28-405, unless such substance was obtained directly or pursuant to a  
20 medical order issued by a practitioner authorized to prescribe while  
21 acting in the course of his or her professional practice, or except as  
22 otherwise authorized by the act, shall be guilty of a Class IV felony. A  
23 person shall not be in violation of this subsection if section 28-472 or  
24 28-1701 applies.

25 (4)(a) Except as authorized by the Uniform Controlled Substances  
26 Act, any person eighteen years of age or older who knowingly or  
27 intentionally manufactures, distributes, delivers, dispenses, or  
28 possesses with intent to manufacture, distribute, deliver, or dispense a  
29 controlled substance or a counterfeit controlled substance (i) to a  
30 person under the age of eighteen years, (ii) in, on, or within one  
31 thousand feet of the real property comprising a public or private

1 elementary, vocational, or secondary school, a community college, a  
2 public or private college, junior college, or university, or a  
3 playground, or (iii) within one hundred feet of a public or private youth  
4 center, public swimming pool, or video arcade facility shall be punished  
5 by the next higher penalty classification than the penalty prescribed in  
6 subsection (2), (7), (8), (9), or (10) of this section, depending upon  
7 the controlled substance involved, for the first violation and for a  
8 second or subsequent violation shall be punished by the next higher  
9 penalty classification than that prescribed for a first violation of this  
10 subsection, but in no event shall such person be punished by a penalty  
11 greater than a Class IB felony.

12 (b) For purposes of this subsection:

13 (i) Playground means any outdoor facility, including any parking lot  
14 appurtenant to the facility, intended for recreation, open to the public,  
15 and with any portion containing three or more apparatus intended for the  
16 recreation of children, including sliding boards, swingsets, and  
17 teeterboards;

18 (ii) Video arcade facility means any facility legally accessible to  
19 persons under eighteen years of age, intended primarily for the use of  
20 pinball and video machines for amusement, and containing a minimum of ten  
21 pinball or video machines; and

22 (iii) Youth center means any recreational facility or gymnasium,  
23 including any parking lot appurtenant to the facility or gymnasium,  
24 intended primarily for use by persons under eighteen years of age which  
25 regularly provides athletic, civic, or cultural activities.

26 (5)(a) Except as authorized by the Uniform Controlled Substances  
27 Act, it shall be unlawful for any person eighteen years of age or older  
28 to knowingly and intentionally employ, hire, use, cause, persuade, coax,  
29 induce, entice, seduce, or coerce any person under the age of eighteen  
30 years to manufacture, transport, distribute, carry, deliver, dispense,  
31 prepare for delivery, offer for delivery, or possess with intent to do

1 the same a controlled substance or a counterfeit controlled substance.

2 (b) Except as authorized by the Uniform Controlled Substances Act,  
3 it shall be unlawful for any person eighteen years of age or older to  
4 knowingly and intentionally employ, hire, use, cause, persuade, coax,  
5 induce, entice, seduce, or coerce any person under the age of eighteen  
6 years to aid and abet any person in the manufacture, transportation,  
7 distribution, carrying, delivery, dispensing, preparation for delivery,  
8 offering for delivery, or possession with intent to do the same of a  
9 controlled substance or a counterfeit controlled substance.

10 (c) Any person who violates subdivision (a) or (b) of this  
11 subsection shall be punished by the next higher penalty classification  
12 than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of  
13 this section, depending upon the controlled substance involved, for the  
14 first violation and for a second or subsequent violation shall be  
15 punished by the next higher penalty classification than that prescribed  
16 for a first violation of this subsection, but in no event shall such  
17 person be punished by a penalty greater than a Class IB felony.

18 (6) It shall not be a defense to prosecution for violation of  
19 subsection (4) or (5) of this section that the defendant did not know the  
20 age of the person through whom the defendant violated such subsection.

21 (7) Any person who violates subsection (1) of this section with  
22 respect to cocaine or any mixture or substance containing a detectable  
23 amount of cocaine in a quantity of:

24 (a) One hundred forty grams or more shall be guilty of a Class IB  
25 felony;

26 (b) At least twenty-eight grams but less than one hundred forty  
27 grams shall be guilty of a Class IC felony; or

28 (c) At least ten grams but less than twenty-eight grams shall be  
29 guilty of a Class ID felony.

30 (8) Any person who violates subsection (1) of this section with  
31 respect to base cocaine (crack) or any mixture or substance containing a

1 detectable amount of base cocaine in a quantity of:

2 (a) One hundred forty grams or more shall be guilty of a Class IB  
3 felony;

4 (b) At least twenty-eight grams but less than one hundred forty  
5 grams shall be guilty of a Class IC felony; or

6 (c) At least ten grams but less than twenty-eight grams shall be  
7 guilty of a Class ID felony.

8 (9) Any person who violates subsection (1) of this section with  
9 respect to heroin or any mixture or substance containing a detectable  
10 amount of heroin in a quantity of:

11 (a) One hundred forty grams or more shall be guilty of a Class IB  
12 felony;

13 (b) At least twenty-eight grams but less than one hundred forty  
14 grams shall be guilty of a Class IC felony; or

15 (c) At least ten grams but less than twenty-eight grams shall be  
16 guilty of a Class ID felony.

17 (10) Any person who violates subsection (1) of this section with  
18 respect to amphetamine, its salts, optical isomers, and salts of its  
19 isomers, or with respect to methamphetamine, its salts, optical isomers,  
20 and salts of its isomers, in a quantity of:

21 (a) One hundred forty grams or more shall be guilty of a Class IB  
22 felony;

23 (b) At least twenty-eight grams but less than one hundred forty  
24 grams shall be guilty of a Class IC felony; or

25 (c) At least ten grams but less than twenty-eight grams shall be  
26 guilty of a Class ID felony.

27 (11) Any person knowingly or intentionally possessing marijuana  
28 weighing more than one ounce but not more than one pound shall be guilty  
29 of a Class III misdemeanor.

30 (12) Any person knowingly or intentionally possessing marijuana  
31 weighing more than one pound shall be guilty of a Class IV felony.

1 (13) Except as provided in section 28-1701, any person knowingly or  
2 intentionally possessing marijuana weighing one ounce or less or any  
3 substance containing a quantifiable amount of the substances, chemicals,  
4 or compounds described, defined, or delineated in subdivision (c)(27) ~~(e)~~  
5 ~~(26)~~ of Schedule I of section 28-405 shall:

6 (a) For the first offense, be guilty of an infraction, receive a  
7 citation, be fined three hundred dollars, and be assigned to attend a  
8 course as prescribed in section 29-433 if the judge determines that  
9 attending such course is in the best interest of the individual  
10 defendant;

11 (b) For the second offense, be guilty of a Class IV misdemeanor,  
12 receive a citation, and be fined four hundred dollars and may be  
13 imprisoned not to exceed five days; and

14 (c) For the third and all subsequent offenses, be guilty of a Class  
15 IIIA misdemeanor, receive a citation, be fined five hundred dollars, and  
16 be imprisoned not to exceed seven days.

17 (14) Any person convicted of violating this section, if placed on  
18 probation, shall, as a condition of probation, satisfactorily attend and  
19 complete appropriate treatment and counseling on drug abuse provided by a  
20 program authorized under the Nebraska Behavioral Health Services Act or  
21 other licensed drug treatment facility.

22 (15) Any person convicted of violating this section, if sentenced to  
23 the Department of Correctional Services, shall attend appropriate  
24 treatment and counseling on drug abuse.

25 (16) Any person knowingly or intentionally possessing a firearm  
26 while in violation of subsection (1) of this section shall be punished by  
27 the next higher penalty classification than the penalty prescribed in  
28 subsection (2), (7), (8), (9), or (10) of this section, but in no event  
29 shall such person be punished by a penalty greater than a Class IB  
30 felony.

31 (17) A person knowingly or intentionally in possession of money used

1 or intended to be used to facilitate a violation of subsection (1) of  
2 this section shall be guilty of a Class IV felony.

3 (18) In addition to the existing penalties available for a violation  
4 of subsection (1) of this section, including any criminal attempt or  
5 conspiracy to violate subsection (1) of this section, a sentencing court  
6 may order that any money, securities, negotiable instruments, firearms,  
7 conveyances, or electronic communication devices as defined in section  
8 28-833 or any equipment, components, peripherals, software, hardware, or  
9 accessories related to electronic communication devices be forfeited as a  
10 part of the sentence imposed if it finds by clear and convincing evidence  
11 adduced at a separate hearing in the same prosecution, following  
12 conviction for a violation of subsection (1) of this section, and  
13 conducted pursuant to section 28-1601, that any or all such property was  
14 derived from, used, or intended to be used to facilitate a violation of  
15 subsection (1) of this section.

16 (19) In addition to the penalties provided in this section:

17 (a) If the person convicted or adjudicated of violating this section  
18 is eighteen years of age or younger and has one or more licenses or  
19 permits issued under the Motor Vehicle Operator's License Act:

20 (i) For the first offense, the court may, as a part of the judgment  
21 of conviction or adjudication, (A) impound any such licenses or permits  
22 for thirty days and (B) require such person to attend a drug education  
23 class;

24 (ii) For a second offense, the court may, as a part of the judgment  
25 of conviction or adjudication, (A) impound any such licenses or permits  
26 for ninety days and (B) require such person to complete no fewer than  
27 twenty and no more than forty hours of community service and to attend a  
28 drug education class; and

29 (iii) For a third or subsequent offense, the court may, as a part of  
30 the judgment of conviction or adjudication, (A) impound any such licenses  
31 or permits for twelve months and (B) require such person to complete no

1 fewer than sixty hours of community service, to attend a drug education  
2 class, and to submit to a drug assessment by a licensed alcohol and drug  
3 counselor; and

4 (b) If the person convicted or adjudicated of violating this section  
5 is eighteen years of age or younger and does not have a permit or license  
6 issued under the Motor Vehicle Operator's License Act:

7 (i) For the first offense, the court may, as part of the judgment of  
8 conviction or adjudication, (A) prohibit such person from obtaining any  
9 permit or any license pursuant to the act for which such person would  
10 otherwise be eligible until thirty days after the date of such order and  
11 (B) require such person to attend a drug education class;

12 (ii) For a second offense, the court may, as part of the judgment of  
13 conviction or adjudication, (A) prohibit such person from obtaining any  
14 permit or any license pursuant to the act for which such person would  
15 otherwise be eligible until ninety days after the date of such order and  
16 (B) require such person to complete no fewer than twenty hours and no  
17 more than forty hours of community service and to attend a drug education  
18 class; and

19 (iii) For a third or subsequent offense, the court may, as part of  
20 the judgment of conviction or adjudication, (A) prohibit such person from  
21 obtaining any permit or any license pursuant to the act for which such  
22 person would otherwise be eligible until twelve months after the date of  
23 such order and (B) require such person to complete no fewer than sixty  
24 hours of community service, to attend a drug education class, and to  
25 submit to a drug assessment by a licensed alcohol and drug counselor.

26 A copy of an abstract of the court's conviction or adjudication  
27 shall be transmitted to the Director of Motor Vehicles pursuant to  
28 sections 60-497.01 to 60-497.04 if a license or permit is impounded or a  
29 juvenile is prohibited from obtaining a license or permit under this  
30 subsection.

31 Sec. 5. Section 30-24,125, Revised Statutes Cumulative Supplement,

1 2022, is amended to read:

2 30-24,125 (a) Thirty days after the death of a decedent, any person  
3 indebted to the decedent or having possession of tangible personal  
4 property or an instrument evidencing a debt, obligation, stock, or chose  
5 in action belonging to the decedent shall make payment of the  
6 indebtedness or deliver the tangible personal property or an instrument  
7 evidencing a debt, obligation, stock, or chose in action to a person  
8 claiming to be the successor of the decedent upon being presented an  
9 affidavit made by or on behalf of the successor stating:

10 (1) the value of all of the personal property in the decedent's  
11 estate, wherever located, less liens and encumbrances, does not exceed  
12 one hundred thousand dollars;

13 (2) thirty days have elapsed since the death of the decedent as  
14 shown in a certified or authenticated copy of the decedent's death  
15 certificate attached to the affidavit;

16 (3) the claiming successor's relationship to the decedent or, if  
17 there is no relationship, the basis of the successor's claim to the  
18 personal property;

19 (4) the person or persons claiming as successors under the affidavit  
20 swear or affirm that all statements in the affidavit are true and  
21 material and further acknowledge that any false statement may subject the  
22 person or persons to penalties relating to perjury under section 28-915;

23 (5) no application or petition for the appointment of a personal  
24 representative is pending or has been granted in any jurisdiction; and

25 (6) the claiming successor is entitled to payment or delivery of the  
26 property.

27 (b) A transfer agent of any security shall change the registered  
28 ownership on the books of a corporation from the decedent to the  
29 successor or successors upon the presentation of an affidavit as provided  
30 in subsection (a).

31 (c) Upon the presentation of an affidavit as provided in subsection

1 (a), the claiming successor may endorse or negotiate any instrument  
2 evidencing a debt belonging to the decedent that is a check, draft, or  
3 other negotiable instrument that is payable to the decedent or the  
4 decedent's estate. Notwithstanding the provisions of section 3-403,  
5 3-417, or 3-420, Uniform Commercial Code, a financial institution  
6 accepting such a check, draft, or other negotiable instrument presented  
7 for deposit in such manner is discharged from all claims for the amount  
8 accepted.

9 (d) ~~(c)~~ In addition to compliance with the requirements of  
10 subsection (a), a person seeking a transfer of a certificate of title to  
11 a motor vehicle, motorboat, all-terrain vehicle, utility-type vehicle, or  
12 minibike shall be required to furnish to the Department of Motor Vehicles  
13 an affidavit showing applicability of this section and compliance with  
14 the requirements of this section to authorize the department to issue a  
15 new certificate of title.

16 Sec. 6. Section 30-2626, Reissue Revised Statutes of Nebraska, is  
17 amended to read:

18 30-2626 (a)(1) ~~(a)~~ If a person alleged to be incapacitated has no  
19 guardian and an emergency exists, the court may, pending notice and  
20 hearing, exercise the power of a guardian or enter an ex parte order  
21 appointing a temporary guardian to address the emergency. The order and  
22 letters of temporary guardianship shall specify the powers and duties of  
23 the temporary guardian, limiting the powers and duties to those necessary  
24 to address the emergency.

25 (2)(i) For purposes of this subdivision (a)(2):

26 (A) Benefits means private or government benefits to which a person  
27 alleged to be incapacitated may be entitled; and

28 (B) Covered county means a county containing a city of the  
29 metropolitan class or a city of the primary class.

30 (ii) Subject to subsection (k) of this section, if a person alleged  
31 to be incapacitated has no guardian and an emergency exists, the court in

1 a covered county may, pending notice and hearing, enter an ex parte order  
2 appointing a temporary guardian for the limited purpose of assisting the  
3 person in applying for, validating, and facilitating eligibility for  
4 benefits.

5 (iii) The limited temporary guardian may access personal and  
6 financial records of such person as necessary to apply for, validate, and  
7 facilitate eligibility for benefits. The order and letters of limited  
8 temporary guardianship shall limit the powers and duties to those  
9 necessary to carry out this subdivision (a)(2).

10 (iv) Third parties, including, but not limited to, financial  
11 institutions, in possession of such person's financial and personal  
12 records related to eligibility for benefits shall provide the limited  
13 temporary guardian access to such records. Records to which a limited  
14 temporary guardian may be entitled include, but are not limited to,  
15 records relating to: Checking, savings, or other bank accounts; household  
16 expenses; health, life, or other insurance; wages; pensions; annuities;  
17 real property; trusts; burial plans; retirement accounts; stocks and  
18 bonds; farm and business equipment; motor vehicles, boats, and motor  
19 homes; immigration status; land contracts; promissory notes and loans;  
20 social security benefits; credit cards; taxes; or any other asset.

21 (b) When the court takes action to exercise the powers of a guardian  
22 or to appoint a temporary guardian under subsection (a) of this section,  
23 an expedited hearing shall be held if requested by the person alleged to  
24 be incapacitated, or by any interested person, if the request is filed  
25 more than ten business days prior to the date set for the hearing on the  
26 petition for appointment of the guardian. If an expedited hearing is to  
27 be held, the hearing shall be held within ten business days after the  
28 request is received. At the hearing on the temporary appointment, the  
29 petitioner shall have the burden of showing by a preponderance of the  
30 evidence that temporary guardianship continues to be necessary to address  
31 the emergency situation. Unless the person alleged to be incapacitated

1 has counsel of his or her own choice, the court may appoint an attorney  
2 to represent the person alleged to be incapacitated at the hearing as  
3 provided in section 30-2619.

4 (c) If an expedited hearing is requested, notice shall be served as  
5 provided in section 30-2625. The notice shall specify that a temporary  
6 guardian has been appointed and shall be given at least twenty-four hours  
7 prior to the expedited hearing.

8 (d) At the expedited hearing, the court may render a judgment  
9 authorizing the temporary guardianship to continue beyond the original  
10 ten-day period. The judgment shall prescribe the specific powers and  
11 duties of the temporary guardian in the letters of temporary guardianship  
12 and shall be effective for a single ninety-day period. For good cause  
13 shown, the court may extend the temporary guardianship for successive  
14 ninety-day periods.

15 (e)(1) ~~(e)~~ The temporary guardianship shall terminate at the end of  
16 the ninety-day period in which the temporary guardianship is valid or at  
17 any time prior thereto if the court deems the circumstances leading to  
18 the order for temporary guardianship no longer exist or if an order has  
19 been entered as a result of a hearing pursuant to section 30-2619 which  
20 has been held during the ninety-day period.

21 (2) When the duties of a limited temporary guardian appointed  
22 pursuant to subdivision (a)(2) of this section have not been completed  
23 within ninety days, the court shall accept notification by such guardian  
24 as good cause for extending the limited temporary guardianship for an  
25 additional ninety days.

26 (f) If the court denies the request for the ex parte order, the  
27 court may, in its discretion, enter an order for an expedited hearing  
28 pursuant to subsections (b) through (e) of this section.

29 (g) If the petitioner requests the entry of an order of temporary  
30 guardianship pursuant to subsection (a) of this section without  
31 requesting an ex parte order, the court may hold an expedited hearing

1 pursuant to subsections (b) through (e) of this section.

2 (h) If an appointed guardian is not effectively performing his or  
3 her duties and the court further finds that the welfare of the  
4 incapacitated person requires immediate action, it may, pending notice  
5 and hearing in accordance with section 30-2220, appoint a temporary  
6 guardian for the incapacitated person for a specified period not to  
7 exceed ninety days. For good cause shown, the court may extend the  
8 temporary guardianship for successive ninety-day periods. A temporary  
9 guardian appointed pursuant to this subsection has only the powers and  
10 duties specified in the previously appointed guardian's letters of  
11 guardianship, and the authority of any permanent guardian previously  
12 appointed by the court is suspended so long as a temporary guardian has  
13 authority.

14 (i) A temporary guardian may be removed at any time. A temporary  
15 guardian shall make any report the court requires, except that a  
16 temporary guardian shall not be required to provide the check or report  
17 under section 30-2602.02. In other respects the provisions of the  
18 Nebraska Probate Code concerning guardians apply to temporary guardians.

19 (j) The court may appoint the Public Guardian as the temporary  
20 guardian pursuant to the Public Guardianship Act.

21 (k)(1) If the Public Guardian is unable to accept appointment as a  
22 limited temporary guardian for the purposes described in subdivision (a)  
23 (2) of this section because the Public Guardian has exceeded the average  
24 ratio described in subsection (2) of section 30-4115, the court shall  
25 appoint an individual to serve as a limited temporary guardian.  
26 Appointments of such limited temporary guardians shall be subject to the  
27 availability of funds appropriated as described in section 7 of this act.  
28 When such funds have been exhausted in a fiscal year, no further  
29 appointments shall be made.

30 (2) An individual appointed as a limited temporary guardian pursuant  
31 to subdivision (a)(2) of this section shall apply to the court for

1 expenses and fees for services performed. The court, upon hearing the  
2 application, shall fix reasonable expenses and fees, and the county board  
3 shall pay such guardian in the full amount determined by the court. The  
4 court shall set such expenses and fees at levels that: (i) Are similar to  
5 expenses and fees paid to guardians and guardians ad litem for comparable  
6 work in other legal proceedings in the county; and (ii) are intended to  
7 incentivize qualified individuals to provide high-quality services as  
8 limited temporary guardians.

9 (3) A county that has paid expenses and fees as provided in  
10 subdivision (k)(2) of this section may apply under section 7 of this act  
11 for reimbursement.

12 Sec. 7. (1) For purposes of this section:

13 (a) Covered county means a county containing a city of the  
14 metropolitan class or a city of the primary class; and

15 (b) Department means the Department of Health and Human Services.

16 (2) There is created a separate and distinct budgetary program  
17 within the department to be known as the Limited Temporary Guardian Aid  
18 Program. Funds appropriated to the program shall be used to provide state  
19 aid to counties in the form of reimbursement to covered counties as  
20 provided in this section.

21 (3) A covered county that has paid expenses and fees for limited  
22 temporary guardians as provided in subdivision (k)(2) of section 30-2626  
23 may apply to the department for reimbursement for such amounts and for  
24 reasonable administrative fees incurred by the county in paying such  
25 amounts and applying for reimbursement. The application shall be in a  
26 form and manner prescribed by the department and shall be submitted on a  
27 quarterly basis.

28 (4) It is the intent of the Legislature to appropriate the following  
29 amounts to the department to carry out the Limited Temporary Guardian Aid  
30 Program:

31 (a) For fiscal year 2024-25:

1        (i) One hundred sixty thousand dollars for state aid under the  
2 program to covered counties containing a city of the metropolitan class;  
3 and

4        (ii) Ninety thousand dollars for state aid under the program to  
5 covered counties containing a city of the primary class; and

6        (b) For fiscal year 2025-26:

7        (i) One hundred sixty thousand dollars for state aid under the  
8 program to covered counties containing a city of the metropolitan class;  
9 and

10       (ii) Ninety thousand dollars for state aid under the program to  
11 covered counties containing a city of the primary class.

12       (5) The department may adopt and promulgate rules and regulations as  
13 necessary to carry out this section.

14       Sec. 8. Section 42-903, Revised Statutes Cumulative Supplement,  
15 2022, is amended to read:

16       42-903 For purposes of the Protection from Domestic Abuse Act,  
17 unless the context otherwise requires:

18       (1) Abuse means the occurrence of one or more of the following acts  
19 between family or household members:

20       (a) Attempting to cause or intentionally and knowingly causing  
21 bodily injury with or without a dangerous instrument;

22       (b) Placing, by means of credible threat, another person in fear of  
23 bodily injury. For purposes of this subdivision, credible threat means a  
24 verbal or written threat, including a threat performed through the use of  
25 an electronic communication device, or a threat implied by a pattern of  
26 conduct or a combination of verbal, written, or electronically  
27 communicated statements and conduct that is made by a person with the  
28 apparent ability to carry out the threat so as to cause the person who is  
29 the target of the threat to reasonably fear for his or her safety or the  
30 safety of his or her family. It is not necessary to prove that the person  
31 making the threat had the intent to actually carry out the threat. The

1 present incarceration of the person making the threat shall not prevent  
2 the threat from being deemed a credible threat under this section; or

3 (c) Engaging in sexual contact or sexual penetration without consent  
4 as defined in section 28-318;

5 (2) Department means the Department of Health and Human Services;

6 (3) Family or household members includes spouses or former spouses,  
7 children, persons who are presently residing together or who have resided  
8 together in the past, persons who have a child in common whether or not  
9 they have been married or have lived together at any time, other persons  
10 related by consanguinity or affinity, and persons who are presently  
11 involved in a dating relationship with each other or who have been  
12 involved in a dating relationship with each other. For purposes of this  
13 subdivision, dating relationship means frequent, intimate associations  
14 primarily characterized by the expectation of affectional or sexual  
15 involvement, but does not include a casual relationship or an ordinary  
16 association between persons in a business or social context;~~and~~

17 (4) Household pet means any animal maintained for companionship or  
18 pleasure but does not include any animal kept primarily for commercial  
19 purposes or for consumption or any livestock animal as defined in section  
20 54-902; and

21 (5) (4) Law enforcement agency means the police department or town  
22 marshal in incorporated municipalities, the office of the sheriff in  
23 unincorporated areas, and the Nebraska State Patrol.

24 Sec. 9. Section 42-924, Revised Statutes Cumulative Supplement,  
25 2022, is amended to read:

26 42-924 (1)(a) Any victim of domestic abuse may file a petition and  
27 affidavit for a protection order as provided in this section. Upon the  
28 filing of such a petition and affidavit in support thereof, the court may  
29 issue a protection order without bond granting the following relief:

30 (i) Enjoining the respondent from imposing any restraint upon the  
31 petitioner or upon the liberty of the petitioner;

1 (ii) Enjoining the respondent from threatening, assaulting,  
2 molesting, attacking, or otherwise disturbing the peace of the  
3 petitioner;

4 (iii) Enjoining the respondent from telephoning, contacting, or  
5 otherwise communicating with the petitioner;

6 (iv) Removing and excluding the respondent from the residence of the  
7 petitioner, regardless of the ownership of the residence;

8 (v) Ordering the respondent to stay away from any place specified by  
9 the court;

10 (vi) Awarding the petitioner temporary custody of any minor children  
11 not to exceed ninety days;

12 (vii) Enjoining the respondent from possessing or purchasing a  
13 firearm as defined in section 28-1201; ~~or~~

14 (viii) Directing that the petitioner have sole possession of any  
15 household pet owned, possessed, leased, kept, or held by the petitioner,  
16 the respondent, or any family or household member residing in the  
17 household of the petitioner or respondent;

18 (ix) Enjoining the respondent from coming into contact with,  
19 harming, or killing any household pet owned, possessed, leased, kept, or  
20 held by the petitioner, the respondent, or any family or household member  
21 of the petitioner or respondent; or

22 (x) ~~(viii)~~ Ordering such other relief deemed necessary to provide  
23 for the safety and welfare of the petitioner and any designated family or  
24 household member.

25 (b) If sole possession of a household pet is ordered by a court  
26 pursuant to subdivision (1)(a)(viii) of this section, such possession  
27 shall be for the duration of the protection order or until further order  
28 of the court. The grant of sole possession of a household pet under such  
29 subdivision is not intended to permanently determine ownership of such  
30 household pet. The petitioner shall not permanently transfer, sell, or  
31 dispose of a household pet placed in the petitioner's possession without

1 prior court approval, except that court approval shall not be required in  
2 cases where humane euthanasia of a seriously ill or injured household pet  
3 is recommended by a licensed veterinarian.

4 (c) (b) The petition for a protection order shall state the events  
5 and dates or approximate dates of acts constituting the alleged domestic  
6 abuse, including the most recent and most severe incident or incidents.

7 (d) (e) The protection order shall specify to whom relief under this  
8 section was granted.

9 (2) Petitions for protection orders shall be filed with the clerk of  
10 the district court, and the proceeding may be heard by the county court  
11 or the district court as provided in section 25-2740. A petition for a  
12 protection order may not be withdrawn except upon order of the court.

13 (3)(a) A protection order shall specify that it is effective for a  
14 period of one year and, if the order grants temporary custody, the number  
15 of days of custody granted to the petitioner unless otherwise modified by  
16 the court.

17 (b)(i) Any victim of domestic abuse may file a petition and  
18 affidavit to renew a protection order. Such petition and affidavit for  
19 renewal shall be filed any time within forty-five days before the  
20 expiration of the previous protection order, including the date the order  
21 expires.

22 (ii) A protection order may be renewed on the basis of the  
23 petitioner's affidavit stating that there has been no material change in  
24 relevant circumstances since entry of the order and stating the reason  
25 for the requested renewal if:

26 (A) The petitioner seeks no modification of the order; and

27 (B)(I) The respondent has been properly served with notice of the  
28 petition for renewal and notice of hearing and fails to appear at the  
29 hearing; or

30 (II) The respondent indicates that he or she does not contest the  
31 renewal.

1 (iii) Such renewed order shall specify that it is effective for a  
2 period of one year to commence on the first calendar day following the  
3 expiration of the previous order or on the calendar day the court grants  
4 the renewal if such day is subsequent to the first calendar day after  
5 expiration of the previous order and, if the court grants temporary  
6 custody, the number of days of custody granted to the petitioner unless  
7 otherwise modified by the court.

8 (4) Any person, except the petitioner, who knowingly violates a  
9 protection order issued pursuant to this section or section 42-931 after  
10 service or notice as described in subsection (2) of section 42-926 shall  
11 be guilty of a Class I misdemeanor, except that any person convicted of  
12 violating such order who has a prior conviction for violating a  
13 protection order shall be guilty of a Class IV felony.

14 (5) If there is any conflict between sections 42-924 to 42-926 and  
15 any other provision of law, sections 42-924 to 42-926 shall govern.

16 Sec. 10. Section 43-286, Revised Statutes Cumulative Supplement,  
17 2022, is amended to read:

18 43-286 (1) When any juvenile is adjudicated to be a juvenile  
19 described in subdivision (1), (2), or (4) of section 43-247:

20 (a) The court may continue the dispositional portion of the hearing,  
21 from time to time upon such terms and conditions as the court may  
22 prescribe, including an order of restitution of any property stolen or  
23 damaged or an order requiring the juvenile to participate in restorative  
24 justice programs or community service programs, if such order is in the  
25 interest of the juvenile's reformation or rehabilitation, and, subject to  
26 the further order of the court, may:

27 (i) Place the juvenile on probation subject to the supervision of a  
28 probation officer; or

29 (ii) Permit the juvenile to remain in his or her own home or be  
30 placed in a suitable family home or institution, subject to the  
31 supervision of the probation officer;

1 (b) When it is alleged that the juvenile has exhausted all levels of  
2 probation supervision and options for community-based services and  
3 section 43-251.01 has been satisfied, a motion for commitment to a youth  
4 rehabilitation and treatment center may be filed and proceedings held as  
5 follows:

6 (i) The motion shall set forth specific factual allegations that  
7 support the motion and a copy of such motion shall be served on all  
8 persons required to be served by sections 43-262 to 43-267;

9 (ii) The Office of Juvenile Services shall be served with a copy of  
10 such motion and shall be a party to the case for all matters related to  
11 the juvenile's commitment to, placement with, or discharge from the  
12 Office of Juvenile Services; and

13 (iii) The juvenile shall be entitled to a hearing before the court  
14 to determine the validity of the allegations. At such hearing the burden  
15 is upon the state by a preponderance of the evidence to show that:

16 (A) All levels of probation supervision have been exhausted;

17 (B) All options for community-based services have been exhausted;  
18 and

19 (C) Placement at a youth rehabilitation and treatment center is a  
20 matter of immediate and urgent necessity for the protection of the  
21 juvenile or the person or property of another or if it appears that such  
22 juvenile is likely to flee the jurisdiction of the court;

23 (c) After the hearing, the court may, as a condition of an order of  
24 intensive supervised probation, commit such juvenile to the Office of  
25 Juvenile Services for placement at a youth rehabilitation and treatment  
26 center operated in compliance with state law. Upon commitment by the  
27 court to the Office of Juvenile Services, the court shall immediately  
28 notify the Office of Juvenile Services of the commitment. Intensive  
29 supervised probation for purposes of this subdivision means that the  
30 Office of Juvenile Services shall be responsible for the care and custody  
31 of the juvenile until the Office of Juvenile Services discharges the

1 juvenile from commitment to the Office of Juvenile Services. Upon  
2 discharge of the juvenile, the court shall hold a review hearing on the  
3 conditions of probation and enter any order allowed under subdivision (1)  
4 (a) of this section;

5 (d) The Office of Juvenile Services shall notify those required to  
6 be served by sections 43-262 to 43-267, all interested parties, and the  
7 committing court of the pending discharge of a juvenile from the youth  
8 rehabilitation and treatment center sixty days prior to discharge and  
9 again in every case not less than thirty days prior to discharge. Upon  
10 notice of pending discharge by the Office of Juvenile Services, the court  
11 shall set a continued disposition hearing in anticipation of reentry. The  
12 Office of Juvenile Services shall work in collaboration with the Office  
13 of Probation Administration in developing an individualized reentry plan  
14 for the juvenile as provided in section 43-425. The Office of Juvenile  
15 Services shall provide a copy of the individualized reentry plan to the  
16 juvenile, the juvenile's attorney, and the county attorney or city  
17 attorney prior to the continued disposition hearing. At the continued  
18 disposition hearing, the court shall review and approve or modify the  
19 individualized reentry plan, place the juvenile under probation  
20 supervision, and enter any other order allowed by law. No hearing is  
21 required if all interested parties stipulate to the individualized  
22 reentry plan by signed motion. In such a case, the court shall approve  
23 the conditions of probation, approve the individualized reentry plan, and  
24 place the juvenile under probation supervision; and

25 (e) The Office of Juvenile Services is responsible for  
26 transportation of the juvenile to and from the youth rehabilitation and  
27 treatment center. The Office of Juvenile Services may contract for such  
28 services. A plan for a juvenile's transport to return to the community  
29 shall be a part of the individualized reentry plan. The Office of  
30 Juvenile Services may approve family to provide such transport when  
31 specified in the individualized reentry plan.

1           (2) When any juvenile is found by the court to be a juvenile  
2 described in subdivision (3)(b) of section 43-247, the court may enter  
3 such order as it is empowered to enter under subdivision (1)(a) of this  
4 section.

5           (3) When any juvenile is adjudicated to be a juvenile described in  
6 subdivision (1), (2), (3)(b), or (4) of section 43-247, the court may  
7 order the juvenile to be assessed for referral to participate in a  
8 restorative justice program. Factors that the judge may consider for such  
9 referral include, but are not limited to: The juvenile's age,  
10 intellectual capacity, and living environment; the ages of others who  
11 were part of the offense; the age and capacity of the victim; and the  
12 nature of the case.

13           (4) When a juvenile is placed on probation and a probation officer  
14 has reasonable cause to believe that such juvenile has committed a  
15 violation of a condition of his or her probation, the probation officer  
16 shall take appropriate measures as provided in section 43-286.01.

17           (5)(a) When a juvenile is placed on probation or under the  
18 supervision of the court and it is alleged that the juvenile is again a  
19 juvenile described in subdivision (1), (2), (3)(b), or (4) of section  
20 43-247, a petition may be filed and the same procedure followed and  
21 rights given at a hearing on the original petition. If an adjudication is  
22 made that the allegations of the petition are true, the court may make  
23 any disposition authorized by this section for such adjudications and the  
24 county attorney may file a motion to revoke the juvenile's probation.

25           (b) When a juvenile is placed on probation or under the supervision  
26 of the court for conduct under subdivision (1), (2), (3)(b), or (4) of  
27 section 43-247 and it is alleged that the juvenile has violated a term of  
28 probation or supervision or that the juvenile has violated an order of  
29 the court, a motion to revoke probation or supervision or to change the  
30 disposition may be filed and proceedings held as follows:

31           (i) The motion shall set forth specific factual allegations of the

1 alleged violations and a copy of such motion shall be served on all  
2 persons required to be served by sections 43-262 to 43-267;

3 (ii) The juvenile shall be entitled to a hearing before the court to  
4 determine the validity of the allegations. At such hearing the juvenile  
5 shall be entitled to those rights relating to counsel provided by section  
6 43-272 and those rights relating to detention provided by sections 43-254  
7 to 43-256. The juvenile shall also be entitled to speak and present  
8 documents, witnesses, or other evidence on his or her own behalf. He or  
9 she may confront persons who have given adverse information concerning  
10 the alleged violations, may cross-examine such persons, and may show that  
11 he or she did not violate the conditions of his or her probation or  
12 supervision or an order of the court or, if he or she did, that  
13 mitigating circumstances suggest that the violation does not warrant  
14 revocation of probation or supervision or a change of disposition. The  
15 hearing shall be held within a reasonable time after the juvenile is  
16 taken into custody;

17 (iii) The hearing shall be conducted in an informal manner and shall  
18 be flexible enough to consider evidence, including letters, affidavits,  
19 and other material, that would not be admissible in an adversarial  
20 criminal trial;

21 (iv) The juvenile shall not be confined, detained, or otherwise  
22 significantly deprived of his or her liberty pursuant to the filing of a  
23 motion described in this section unless the requirements of subdivision  
24 (5) of section 43-251.01 and section 43-260.01 have been met. In all  
25 cases when the requirements of subdivision (5) of section 43-251.01 and  
26 section 43-260.01 have been met and the juvenile is confined, detained,  
27 or otherwise significantly deprived of his or her liberty as a result of  
28 his or her alleged violation of probation, supervision, or a court order,  
29 the juvenile shall be given a preliminary hearing. If, as a result of  
30 such preliminary hearing, probable cause is found to exist, the juvenile  
31 shall be entitled to a hearing before the court in accordance with this

1 subsection;

2 (v) If the juvenile is found by the court to have violated the terms  
3 of his or her probation or supervision or an order of the court, the  
4 court may modify the terms and conditions of the probation, supervision,  
5 or other court order, extend the period of probation, supervision, or  
6 other court order, or enter any order of disposition that could have been  
7 made at the time the original order was entered; and

8 (vi) In cases when the court revokes probation, supervision, or  
9 other court order, it shall enter a written statement as to the evidence  
10 relied on and the reasons for revocation.

11 (6)(a) Except as provided in subdivision (6)(b) of this section, the  
12 court shall not change a disposition unless the court finds that the  
13 juvenile has violated a term or condition of probation or supervision or  
14 an order of the court and the procedures in subdivision (5)(b) of this  
15 section have been satisfied.

16 (b) Upon motion of the juvenile, the court may modify the terms or  
17 conditions of probation or supervision or modify a dispositional order  
18 if:

19 (i) All parties stipulate to the particular modification; and

20 (ii) The juvenile has consulted with counsel or has waived counsel.  
21 Any waiver must be particular to the modification and shall comply with  
22 section 43-3102.

23 ~~(7) (6)~~ Costs incurred on behalf of a juvenile under this section  
24 shall be paid as provided in section 43-290.01.

25 ~~(8) (7)~~ When any juvenile is adjudicated to be a juvenile described  
26 in subdivision (4) of section 43-247, the juvenile court shall within  
27 thirty days of adjudication transmit to the Director of Motor Vehicles an  
28 abstract of the court record of adjudication.

29 Sec. 11. Section 52-401, Reissue Revised Statutes of Nebraska, is  
30 amended to read:

31 52-401 (1) Whenever any person employs a physician, nurse,

1    chiropractor, ~~or~~ hospital, or provider of emergency medical service to  
2    perform professional ~~service~~ or services of any nature, in the treatment  
3    of or in connection with an injury, and such injured person claims  
4    damages from the party causing the injury, such physician, nurse,  
5    chiropractor, ~~or~~ hospital, or provider of emergency medical service as  
6    ~~the case may be~~, shall have a lien upon any sum awarded the injured  
7    person in judgment or obtained by settlement or compromise on the amount  
8    due for the usual and customary charges of such physician, nurse,  
9    chiropractor, ~~or~~ hospital, or provider of emergency medical service  
10   applicable at the time ~~times~~ services are performed, except that no such  
11   lien shall be valid against anyone covered ~~coming~~ under the Nebraska  
12   Workers' Compensation Act. For persons covered under private medical  
13   insurance or another private health benefit plan, the amount of the lien  
14   shall be reduced by the contracted discount or other limitation which  
15   would have been applied had the claim been submitted for reimbursement to  
16   the medical insurer or administrator of such other health benefit plan.  
17   The measure of damages for medical expenses in personal injury claims  
18   shall be the private party rate, not the discounted amount.

19        (2) In order to prosecute such lien, it shall be necessary for such  
20   physician, nurse, chiropractor, ~~or~~ hospital, or provider of emergency  
21   medical service to serve a written notice upon the person or corporation  
22   from whom damages are claimed that such physician, nurse, chiropractor,  
23   ~~or~~ hospital, or provider of emergency medical service claims a lien for  
24   such services and stating the amount due and the nature of such services,  
25   except that whenever an action is pending in court for the recovery of  
26   such damages, it shall be sufficient to file the notice of such lien in  
27   the pending action.

28        (3) A physician, nurse, chiropractor, ~~or~~ hospital, or provider of  
29   emergency medical service claiming a lien under this section shall not be  
30   liable for attorney's fees and costs incurred by the injured person in  
31   securing the judgment, settlement, or compromise, but the lien of the

1 injured person's attorney shall have precedence over the lien created by  
2 this section.

3 (4) Upon a written request and with the injured person's consent, a  
4 lienholder shall provide medical records, answers to interrogatories,  
5 depositions, or any expert medical testimony related to the recovery of  
6 damages within its custody and control at a reasonable charge to the  
7 injured person.

8 (5) For purposes of this section, provider of emergency medical  
9 service means a public entity that provides emergency medical service as  
10 defined in section 38-1207.

11 Sec. 12. Section 81-1821, Revised Statutes Cumulative Supplement,  
12 2022, is amended to read:

13 81-1821 (1) Except as provided in subsections (3) and (4) ~~subsection~~  
14 ~~{2}~~ of this section, no order for the payment of compensation shall be  
15 entered under the Nebraska Crime Victim's Reparations Act unless:

16 (a) The the application has been submitted to the committee within  
17 the deadline provided in subsection (2) of this section; and

18 (b) The within two years after the date of the personal injury or  
19 death and the personal injury or death was the result of an incident or  
20 offense which had been reported to the police within five ~~three~~ days of  
21 its occurrence or, if the incident or offense could not reasonably have  
22 been reported within that period, within five ~~three~~ days of the time when  
23 a report could reasonably have been made.

24 (2) An application shall be submitted to the committee:

25 (a) For a victim who was nineteen years of age or older at the time  
26 of the personal injury or death, within two years after the date of the  
27 personal injury or death;

28 (b) For a victim who was under nineteen years of age at the time of  
29 death, within three years after the date of death; and

30 (c) For a victim who was under nineteen years of age at the time of  
31 the personal injury, on or before the victim's twenty-second birthday.

1           (3) The committee may evaluate applications submitted beyond the  
2 deadline established in this section if the committee finds that good  
3 cause existed for missing such deadline.

4           (4) ~~(2)~~ An application submitted by or for a victim of sexual  
5 assault, domestic assault, child abuse, or sex trafficking is not subject  
6 to the five-day ~~three-day~~ reporting requirement in subsection (1) of this  
7 section if, prior to submitting the application the:

8           (a) Applicant or victim has reported such crime to the police;

9           (b) Applicant or victim has obtained a protection order related to  
10 such incident or offense; or

11           (c) Victim has presented for a forensic medical exam.

12           Sec. 13. Section 83-4,114, Revised Statutes Cumulative Supplement,  
13 2022, is amended to read:

14           83-4,114 (1) There shall be no corporal punishment or disciplinary  
15 restrictions on diet.

16           (2) Disciplinary restrictions on clothing, bedding, mail,  
17 visitations, use of toilets, washbowls, or scheduled showers shall be  
18 imposed only for abuse of such privilege or facility and only as  
19 authorized by written directives, guidance documents, and operational  
20 manuals.

21           (3) No person shall be placed in solitary confinement.

22           (4) The director shall issue an annual report on or before September  
23 15 to the Governor and the Clerk of the Legislature. The report to the  
24 Clerk of the Legislature shall be issued electronically. For all inmates  
25 who were held in restrictive housing during the prior year, the report  
26 shall contain the race, gender, age, and length of time each inmate has  
27 continuously been held in restrictive housing. ~~Prior to releasing the~~  
28 ~~report, the director shall meet with the long-term restrictive housing~~  
29 ~~work group to share the contents of the report.~~ The report shall also  
30 contain:

31           (a) The number of inmates held in restrictive housing;

1 (b) The reason or reasons each inmate was held in restrictive  
2 housing;

3 (c) The number of inmates held in restrictive housing who have been  
4 diagnosed with a mental illness or behavioral disorder and the type of  
5 mental illness or behavioral disorder by inmate;

6 (d) The number of inmates who were released from restrictive housing  
7 directly to parole or into the general public and the reason for such  
8 release;

9 (e) The number of inmates who were placed in restrictive housing for  
10 his or her own safety and the underlying circumstances for each  
11 placement;

12 (f) To the extent reasonably ascertainable, comparable statistics  
13 for the nation and each of the states that border Nebraska pertaining to  
14 subdivisions (4)(a) through (e) of this section; ~~and~~

15 (g) The mean and median length of time for all inmates held in  
16 restrictive housing; ~~and -~~

17 (h) A description of all inmate housing areas that hold inmates in a  
18 setting that is neither general population nor restrictive housing,  
19 including the purpose of each setting, data on how many inmates were held  
20 in such settings, the average length of stay in such settings,  
21 information on programs provided in each setting, data on program  
22 completions in each setting, staffing levels and types of staff in each  
23 setting, and any other information or data relevant to the operation of  
24 such settings. For the purposes of this subdivision, general population  
25 means an inmate housing area that allows out-of-cell movement without the  
26 use of restraints, a minimum of six hours per day of out-of-cell time,  
27 regular access to programming areas outside the living unit, and access  
28 to services available to the broader population.

29 ~~(5)(a) There is hereby established within the department a long-term~~  
30 ~~restrictive housing work group. The work group shall consist of one~~  
31 ~~member of the Judiciary Committee of the Legislature appointed by the~~

1 ~~Executive Board of the Legislative Council who shall be a nonvoting, ex~~  
2 ~~officio member and the following voting members:~~

3 ~~(i) The director and all deputy directors who have oversight over~~  
4 ~~inmate health services or correctional facilities. The director or his or~~  
5 ~~her designee shall serve as the chairperson of the work group;~~

6 ~~(ii) The behavioral health administrator within the department;~~

7 ~~(iii) Two employees of the department who currently work with~~  
8 ~~inmates held in restrictive housing as designated by the director;~~

9 ~~(iv) Additional department staff as designated by the director; and~~

10 ~~(v) Six members appointed by the Governor who have demonstrated an~~  
11 ~~interest in correctional issues. Of these members at least one shall be~~  
12 ~~an individual who was previously incarcerated in Nebraska's correctional~~  
13 ~~system. The remaining members shall consist of individuals who are mental~~  
14 ~~health professionals, have been employed in a restrictive housing unit in~~  
15 ~~a correctional facility, have advocated for the rights of incarcerated~~  
16 ~~individuals, or have otherwise been engaged in activities related to~~  
17 ~~Nebraska's correctional system.~~

18 ~~(b) The work group shall advise the department on policies and~~  
19 ~~procedures related to the proper treatment and care of offenders in long-~~  
20 ~~term restrictive housing.~~

21 ~~(c) The director shall convene the work group's first meeting no~~  
22 ~~later than September 15, 2015, and the work group shall meet at least~~  
23 ~~semiannually thereafter. The chairperson shall schedule and convene the~~  
24 ~~work group's meetings.~~

25 ~~(d) The director shall provide the work group with quarterly updates~~  
26 ~~on the department's policies related to the work group's subject matter~~  
27 ~~and with any other information related to long-term restrictive housing~~  
28 ~~that is requested by members of the work group.~~

29 ~~(e) The work group shall terminate on December 31, 2021.~~

30 Sec. 14. Section 83-918, Revised Statutes Cumulative Supplement,  
31 2022, is amended to read:

1           83-918 (1) For each the biennium ~~ending June 30, 2019, and the~~  
2 ~~biennium ending June 30, 2021~~, the Department of Correctional Services  
3 shall, as part of the appropriations request process pursuant to  
4 subsection (1) of section 81-132, include a strategic plan that  
5 identifies the main purpose or purposes of each program, verifiable and  
6 auditable key goals that the department believes are fair measures of its  
7 progress in meeting each program's main purpose or purposes, and  
8 benchmarks for improving performance on the key goals. The department  
9 shall also report whether the benchmarks are being met and, if not, the  
10 expected timeframes for meeting them.

11           (2) On or before ~~Not later than~~ September 15 of each year in ~~2017,~~  
12 ~~2018, 2019, 2020, and 2021~~, the Department of Correctional Services shall  
13 report electronically to the Judiciary Committee of the Legislature and  
14 the Appropriations Committee of the Legislature on the progress towards  
15 the key goals identified pursuant to this section that occurred in the  
16 previous twelve months. Upon request ~~In calendar years 2017, 2018, 2019,~~  
17 ~~2020, and 2021~~, the department shall appear at a joint hearing of the  
18 Judiciary Committee and Appropriations Committee and present the report.

19           Sec. 15. Sections 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17,  
20 and 18 of this act become operative three calendar months after the  
21 adjournment of this legislative session. The other sections of this act  
22 become operative on their effective date.

23           Sec. 16. Original section 30-24,125, Revised Statutes Cumulative  
24 Supplement, 2022, is repealed.

25           Sec. 17. Original sections 25-21,273, 30-2626, and 52-401, Reissue  
26 Revised Statutes of Nebraska, and sections 28-405, 28-416, 42-903,  
27 42-924, 43-286, 81-1821, 83-4,114, and 83-918, Revised Statutes  
28 Cumulative Supplement, 2022, are repealed.

29           Sec. 18. The following section is outright repealed: Section  
30 83-173.02, Revised Statutes Cumulative Supplement, 2022.

31           Sec. 19. Since an emergency exists, this act takes effect when

1 passed and approved according to law.

2 2. On page 1, strike beginning with "temporary guardians" in line 1  
3 through line 5 and insert "law; to amend sections 25-21,273, 30-2626, and  
4 52-401, Reissue Revised Statutes of Nebraska, and sections 28-405,  
5 28-416, 30-24,125, 42-903, 42-924, 43-286, 81-1821, 83-4,114, and 83-918,  
6 Revised Statutes Cumulative Supplement, 2022; to allow petitioners in  
7 change of name proceedings to proceed in forma pauperis; to prohibit  
8 providers of services relating to examination or treatment of injuries  
9 from sexual assault, domestic assault, and child abuse from taking  
10 certain debt enforcement actions against victims; to change provisions  
11 relating to controlled substances schedules under the Uniform Controlled  
12 Substances Act; to change provisions relating to decedents' estates; to  
13 authorize appointment of temporary guardians for certain limited purposes  
14 in certain counties; to create the Limited Temporary Guardian Aid Program  
15 and provide state aid to covered counties; to provide for protection of  
16 household pets in protection orders under the Protection from Domestic  
17 Abuse Act; to provide for modification of disposition orders or  
18 conditions of probation or supervision under the Nebraska Juvenile Code;  
19 to provide for a lien for providers of emergency medical services; to  
20 change requirements for applications to the Crime Victim's Reparations  
21 Committee; to provide a duty for the Department of Correctional Services  
22 and to change provisions relating to certain reports; to eliminate  
23 obsolete provisions relating to the long-term restrictive housing work  
24 group; to eliminate a reporting requirement related to the use of  
25 restrictive housing; to harmonize provisions; to provide operative dates;  
26 to repeal the original sections; to outright repeal section 83-173.02,  
27 Revised Statutes Cumulative Supplement, 2022; and to declare an  
28 emergency.".